# Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema

> **NCT01882712** · PHASE3 · WITHDRAWN · sponsor: **Galderma R&D**

## Conditions studied

- Erythema

## Interventions

- **DRUG:** CD07805/47 Gel 0.5%
- **DRUG:** CD07805/47 Gel Placebo

## Key facts

- **NCT ID:** NCT01882712
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2015-09
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01882712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01882712, "Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01882712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*